SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Appelbaum PS, Roth IH, Lidz CW, et al. False hope and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987; 17: 20-24.
  • 2
    Weinfurt KP, Castel LD, Li Y, et al. The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer. 2003; 98: 166-175.
  • 3
    Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol. 2000; 18: 421-428.
  • 4
    Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995; 13: 1062-1072.
  • 5
    Miller M. Phase 1 cancer trials: a collusion of misunderstanding. Hastings Cent Rep. 2000; 30: 34-42.
  • 6
    Horng S, Emanuel EJ, Wilfond B, et al. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med. 2002; 347: 2134-2140.
  • 7
    Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991-2002. N Engl J Med. 2005; 352: 895-904.
  • 8
    Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med. 2005; 352: 930-932.
  • 9
    Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol. 2006; 24: 2987-2990.
  • 10
    Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. 2003; 25: 11-16.
  • 11
    Weinfurt KP, Sulmasy DP, Schulman KA, et al. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth. 2003; 24: 329-344.
  • 12
    Weinfurt KP. Discursive versus information-processing perspectives on a bioethical problem: the case of “unrealistic” patient expectations. Theory Psychol. 2004; 14: 191-203.
  • 13
    Weinfurt KP, Seils DM, Tzeng JP, et al. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making. 2008; 28: 575-581.
  • 14
    Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003; 290: 1075-1082.
  • 15
    Rodenhuis S, van den Heuvel WJ, Annyas AA, et al. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984; 20: 457-462.
  • 16
    Yoder LH, O'Rourke TJ, Etnyre A, et al. Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum. 1997; 24: 891-896.
  • 17
    Schutta KM, Burnett CB. Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum. 2000; 27: 1435-1438.
  • 18
    Moore S. A need to try everything: patient participation in phase I trials. J Adv Nurs. 2001; 33: 738-747.
  • 19
    Nurgat ZA, Craig W, Campbell NC, et al. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer. 2005; 92: 1001-1005.
  • 20
    Catania C, De Pas T, Goldhirsch A, et al. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology. 2008; 74: 177-187.
  • 21
    Wendler D, Krohmal B, Emanuel EJ, et al. Why patients continue to participate in clinical research. Arch Intern Med. 2008; 168: 1294-1299.
  • 22
    Jansen LA. The problem with optimism in clinical trials. IRB. 2006; 28: 13-19.
  • 23
    Sandelowski M. Sample size in qualitative research. Res Nurs Health. 1995; 18: 179-183.
  • 24
    Corbin J. Strauss A. Basics of Qualitative Research. Thousand Oaks, CA: Sage; 2008: 143-150.
  • 25
    Hacking I. The Emergence of Probability. Cambridge, UK: Cambridge University Press; 1975.
  • 26
    Strauss A. Qualitative Analysis for Social Scientists. Cambridge, UK: Cambridge University Press; 1987.
  • 27
    Creswell JW, Fetters MD, Ivankova NV. Designing a mixed methods study in primary care. Ann Fam Med. 2004; 2: 7-12.
  • 28
    Austin JL. How to Do Things With Words. 2nd ed. Cambridge, MA: Harvard University Press; 1975.
  • 29
    Kim SY, Schrock L, Wilson RM, et al. An approach to evaluating the therapeutic misconception. IRB. 2009; 31: 7-14.
  • 30
    Hippocrates: Decorum, XVI. In: Jones WHS (trans): Hippocrates. Vol 2. Cambridge, MA: Harvard University Press; 1923: 296-299.
  • 31
    Percival T. In: Leake CD, ed. Percival's Medical Ethics. Huntington, NY: Robert E. Krieger; 1975: 91.
  • 32
    Menninger K. Hope. Am J Psychiatry. 1959; 116: 482-491.
  • 33
    Delvecchio Good MJ, Good BJ, Schaffer C, Lind SE. American oncology and the discourse on hope. Cult Med Psychiatry. 1990; 14: 59-79.
  • 34
    Kodish E, Post SG. Oncology and hope. J Clin Oncol. 1995; 13: 1817-1822.
  • 35
    Lupton D. Medicine as Culture: Illness, Disease, and the Body in Western Societies. 2nd ed. Thousand Oaks, CA: Sage; 2003.
  • 36
    Coyne JC, Pajak TF, Harris J, et al. Radiation therapy oncology group. emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer. 2007; 110: 2568-2575.
  • 37
    Kurtz ME, Kurtz JC, Given CW, et al. Patient optimism and mastery-do they play a role in cancer patients' management of pain and fatigue? J Pain Symptom Manage. 2008; 36: 1-10.
  • 38
    Satterfield JM. Optimism, culture, and history: the roles of explanatory style, integrative complexity, and pessimistic rumination. In: Gillham J, ed. The Science of Optimism and Hope. Radnor, PA: Templeton Foundation Press; 2000: 349-378.
  • 39
    Daugherty CK, Fitchett G, Murphy PE, et al. Trusting God and medicine: spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology. 2005; 14: 135-146.
  • 40
    Lerner BH. The Breast Cancer Wars: Hope, Fear, and the Pursuit of a Cure in Twentieth Century America. New York, NY: Oxford University Press; 2001.
  • 41
    Eliott J, Olver I. The discursive properties of “hope”: a qualitative analysis of cancer patients' speech. Qual Health Res. 2002; 12: 173-193.
  • 42
    Eliott JA, Olver IN. Hope and hoping in the talk of dying cancer patients. Soc Sci Med. 2007; 64: 138-149.
  • 43
    Martin E. Flexible Bodies. Boston, MA: Beacon Press; 1994: 54.
  • 44
    Sulmasy DP, Sugarman J. The many methods of medical ethics (or, 13 ways of looking at a blackbird). In: Sugarman J, Sulmasy DP, eds. Methods in Medical Ethics. Washington, DC: Georgetown University Press; 2001: 3-18.
  • 45
    Murphy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.